Yet how will our system contemplate funding high-cost therapies that deliver potentially curative benefits over such a wide range of years - from 5 to 75 years.
New CAR-T data once again highlights the evaluation challenge
June 5, 2019 Latest NewsNews of the Day
Latest Video
New Stories
-
Dimerix says first ACTION3 trial site activated in Japan and first milestone payment triggered
May 30, 2025 - - Australian Biotech -
Arrotex Pharmaceuticals appointed exclusive partner for Juniper Biologics
May 29, 2025 - - Latest News -
TGA approves new therapy for children with growth hormone deficiency
May 29, 2025 - - Latest News -
AbbVie Australia appoints Dr Carly Levetan associate medical director
May 29, 2025 - - Latest News -
For patients, it's about understanding their experience and accessing the touchpoints
May 29, 2025 - - Latest News -
Priceline Pharmacy launches annual event with national menopause project
May 28, 2025 - - Latest News -
Anne Ruston welcomes her reappointment to health and the addition of NDIS
May 28, 2025 - - Latest News